IPP Bureau
Roche introduces cobas infinity edge
By IPP Bureau - January 11, 2022
Cobas infinity edge is designed as an open platform, allowing healthcare professionals to easily access and adopt third-party innovators’ new digital tools and medically-relevant applications via the Roche digital marketplace
Aurobindo’s CuraTeQ and Orion expand licencing deal in select European markets
By IPP Bureau - January 11, 2022
CuraTeQ and Orion had entered into a licensing agreement, granting marketing and distribution rights for CuraTeQ’s biosimilar products under development in the Nordic states, Austria, Hungary and Slovenia
Algorithmic Biologics receives seed funding from Axilor Lab
By IPP Bureau - January 11, 2022
The company’s platform technology works like a compression algorithm for molecular testing and has applications in healthcare, pharmaceuticals, agriculture, animal husbandry, food safety, synthetic biology, and molecular biology research
Mylab’s CoviSelf can detect Omicron: Study
By IPP Bureau - January 10, 2022
Recent Study by Columbia University finds Mylab’s CoviSelf can detect the Omicron variant successfully
Odisha is the first state to place order for OmiSure to detect Omicron
By IPP Bureau - January 10, 2022
TATA MD’s OmiSure is the only test approved by the ICMR for RT-PCR detection of the Omicron variant
Novartis and Molecular Partners report positive data for anti-viral Covid therapy
By IPP Bureau - January 10, 2022
Topline results from the randomized EMPATHY Part A study in acute Covid-19 ambulatory patients comparing single intravenous doses of ensovibep, a DARPin antiviral therapeutic candidate vs. placebo, met the primary endpoint of viral load reduction over eight days
Alembic receives tentative U.S.FDA approval for dronedarone tablets
By IPP Bureau - January 10, 2022
Dronedarone tablets USP, 400 mg have an estimated market size of US $ 500 million for twelve months ending September 2021 according to IQVIA
Arch Pharmalabs signs agreement with Orchem Technologies to use SMB platform
By IPP Bureau - January 10, 2022
Simulated Moving Bed (SMB) technology is a highly engineered process for implementing chromatographic separation
Clarivate identifies seven potential blockbuster drugs in Annual Drugs to Watch report
By IPP Bureau - January 10, 2022
Despite the challenges of pandemic disruptions, drug developers advance promising therapies for conditions, including Alzheimer's, diabetes and asthma
Bayer and Mammoth Biosciences to collaborate on gene editing technology
By IPP Bureau - January 10, 2022
Under the terms of the agreement, Mammoth Biosciences will receive an upfront payment of USD 40 million, potential future payments of more than one billion USD upon successful achievement of certain research, development, and commercial milestones
Moderna and Carisma Therapeutics partner to develop CAR-M therapeutics
By IPP Bureau - January 10, 2022
Carisma to receive US $ 45 million up-front cash payment and investment by Moderna in the form of a US $ 35 million convertible note
Novavax and Serum file EUA for Covovax in South Africa
By IPP Bureau - January 10, 2022
Novavax' vaccine has received authorizations of the vaccine in over 170 countries
Indica Labs receive CE Mark for its HALO AP
By IPP Bureau - January 10, 2022
The HALO AP platform was developed by Indica Labs to address the specific needs of anatomic pathology labs by supporting a wide range of tissue-based workflows, including primary diagnosis, secondary consults, tumour boards, clinical trials, synoptic reporting, quantitative analytics, and AI
Covaxin booster dose study shows promising results
By IPP Bureau - January 08, 2022
Six months after receipt of the second Covaxin dose, participants received booster dose of the same. The trial demonstrated long-term safety with no serious events
Moderna Covid-19 boosters after five-month interval: U.S. FDA
By IPP Bureau - January 08, 2022
Earlier last week the U.S. FDA had also shortened the time to receive a Pfizer booster shot from six months to five months for everyone 12 and older
